Atea Pharmaceuticals, Inc. (AVIR)
Atea Pharmaceuticals develops oral antiviral medicines for hepatitis C and hepatitis E, and none are yet approved. It last closed at $3.96 on Nov 17, down 3.88% on the day. AVIR last reported earnings on Wed, Aug 12, 2026.
Key Stats
Last 12 monthsNot reported for this period.
From AVIR's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 1 analyst who set a price target on AVIR in the past 90 days. The average target is $8.00, with a high of $8.00 and a low of $8.00, compared with the last close of $3.96.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 16 | Morgan Stanley | Target raised | Hold | $7 → $8 |
| Aug 13 | Morgan Stanley | Maintained | Hold | $7 |
Technical Analysis
The stock is 6% below its 20 day and 19% below its 50 day average. It is 25% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 36), near oversold. The nearest support is the swing low (Nov 2) at $3.94, and the nearest resistance the Pivot at $3.98.
| RSI (14) | 36.40 | Weak, oversold below 30 | Neutral |
| MACD | -0.15 | Above its signal line | Bullish |
| Stochastic | 37.5 | Middle of its range | Neutral |
| ADX (14) | 25.8 | Trending down | |
| Williams %R | -83.1 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -184.3 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −5.0% | Change over 10 sessions | Bearish |
| ATR (14) | $0.25 | Typical daily range, 6.2% of price |
| RSI (14) | 38.34 | Weak, oversold below 30 | Neutral |
| MACD | -0.16 | Below its signal line | Bearish |
| Stochastic | 14.5 | Near the bottom of its range | Oversold |
| ADX (14) | 17.1 | No clear trend | |
| Williams %R | -94.6 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -128.8 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −25.4% | Change over 10 sessions | Bearish |
| ATR (14) | $0.54 | Typical daily range, 13.6% of price |
What happened before
See how AVIR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How AVIR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in AVIR in the last 90 days.
AVIR Institutional Ownership
Full report →- ▲59 buying vs 48 selling
- ▼Held by funds -0.5 pts
- ●Funds holding +1
- ▼Superinvestors: 0 added, 3 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 127 | 126 | +0.8% |
| In funds' top 10 | 1 | 1 | 0.0% |
| Held by funds | 73.5% | 74.0% | −0.5 pts |
| New / increased | 14 / 45 | 19 / 45 | −7.8% |
| Reduced / sold out | 36 / 12 | 38 / 20 | −17.2% |
| Put/call ratio | 0.00 | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AVIR is in one of them and how their past AVIR trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered AVIR in an article yet. Here's the latest on the wider market.
About Atea Pharmaceuticals
Atea Pharmaceuticals is a biopharmaceutical company based in Boston, Massachusetts. It is developing oral antiviral medicines for serious viral diseases. Its main candidates are a two drug regimen for hepatitis C, which is still in clinical trials, and a treatment for hepatitis E in patients with weakened immune systems. The company builds these candidates from a proprietary platform of nucleotide compounds.
- Headquarters
- Boston, MA


